Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Guichard, S; Montazeri, A; Chatelut, E; Hennebelle, I; Bugat, R; Canal, P
   Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation
   CLINICAL CANCER RESEARCH
   
   S. Guichard et al., "Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation", CLIN CANC R, 7(10), 2001, pp. 3222-3228
2. Guichard, S; Arnould, S; Hennebelle, I; Bugat, R; Canal, P
   Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo
   ANTI-CANCER DRUGS
   
   S. Guichard et al., "Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo", ANTI-CANC D, 12(9), 2001, pp. 741-751
3. Patoux, A; Bleyzac, N; Boddy, AV; Doz, F; Rubie, H; Bastian, G; Maire, P; Canal, P; Chatelut, E
   Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children
   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
   
   A. Patoux et al., "Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children", EUR J CL PH, 57(4), 2001, pp. 297-303
4. Guichard, S; Canal, P
   New techniques and methods in cancer chemotherapy
   BULLETIN DU CANCER
   
   S. Guichard e P. Canal, "New techniques and methods in cancer chemotherapy", B CANCER, 88(1), 2001, pp. 85-89
5. Chatelut, E; Pivot, X; Otto, J; Chevreau, C; Thyss, A; Renee, N; Milano, G; Canal, P
   A limited sampling strategy for determining carboplatin AUC and monitoringdrug dosage
   EUROPEAN JOURNAL OF CANCER
   
   E. Chatelut et al., "A limited sampling strategy for determining carboplatin AUC and monitoringdrug dosage", EUR J CANC, 36(2), 2000, pp. 264-269
6. Hennebelle, I; Terret, C; Chatelut, E; Bugat, R; Canal, P; Guichard, S
   Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitra-phenylacetate converting carboxylesterase activity
   ANTI-CANCER DRUGS
   
   I. Hennebelle et al., "Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitra-phenylacetate converting carboxylesterase activity", ANTI-CANC D, 11(6), 2000, pp. 465-470
7. Solary, E; Mannone, L; Moreau, D; Caillot, D; Casasnovas, RO; Guy, H; Grandjean, M; Wolf, JE; Andre, F; Fenaux, P; Canal, P; Chauffert, B; Wotawa, A; Bayssas, M; Gennes, P
   Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes
   LEUKEMIA
   
   E. Solary et al., "Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes", LEUKEMIA, 14(12), 2000, pp. 2085-2094
8. Fournet, A; Gilard, V; Malet-Martino, M; Martino, R; Canal, P; De Forni, M
   Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump
   CANCER CHEMOTHERAPY AND PHARMACOLOGY
   
   A. Fournet et al., "Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump", CANC CHEMOT, 46(6), 2000, pp. 501-506
9. Montazeri, A; Boucaud, M; Lokiec, F; Pinguet, F; Culine, S; Deporte-Fety, R; Albin, N; Laguerre, B; Goupil, A; Bugat, R; Canal, P; Chatelut, E
   Population pharmacokinetics of topotecan: intraindividual variability in total drug
   CANCER CHEMOTHERAPY AND PHARMACOLOGY
   
   A. Montazeri et al., "Population pharmacokinetics of topotecan: intraindividual variability in total drug", CANC CHEMOT, 46(5), 2000, pp. 375-381
10. Guimbaud, R; Guichard, S; Dusseau, C; Bertrand, V; Aparicio, T; Lochon, I; Chatelut, E; Couturier, D; Bugat, R; Chaussade, S; Canal, P
    Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    R. Guimbaud et al., "Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans", CANC CHEMOT, 45(6), 2000, pp. 477-482
11. Canal, P; Kowalkowski, J; Maeshima, K; Yu, J; Wenzel, H; Snow, J; Arisawa, T; Ikado, K; Shimojima, M; Veramendi, G
    Online monitoring in the upcoming Fermilab Tevatron runII
    IEEE TRANSACTIONS ON NUCLEAR SCIENCE
    
    P. Canal et al., "Online monitoring in the upcoming Fermilab Tevatron runII", IEEE NUCL S, 47(2), 2000, pp. 240-243
12. Terret, C; Erdociain, E; Guimbaud, R; Boisdron-Celle, M; McLeod, HL; Fety-Deporte, R; Lafont, T; Gamelin, E; Bugat, R; Canal, P; Chatelut, E
    Dose and time dependencies of 5-fluorouracil pharmacokinetics
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    C. Terret et al., "Dose and time dependencies of 5-fluorouracil pharmacokinetics", CLIN PHARM, 68(3), 2000, pp. 270-279
13. Chatelut, E; Canal, P; Bugat, R
    Pharmacokinetics and dose adjustment of carboplatin
    BULLETIN DU CANCER
    
    E. Chatelut et al., "Pharmacokinetics and dose adjustment of carboplatin", B CANCER, 87, 2000, pp. 17-23
14. Canal, P
    Photosynthesis and 'inverse respiration' in plants: an inevitable misconception?
    INTERNATIONAL JOURNAL OF SCIENCE EDUCATION
    
    P. Canal, "Photosynthesis and 'inverse respiration' in plants: an inevitable misconception?", INT J SCI E, 21(4), 1999, pp. 363-371
15. Perdaems, N; Caunes, N; Canal, P; Chatelut, E
    Possible excretion at etoposide via the intestinal mucosa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    N. Perdaems et al., "Possible excretion at etoposide via the intestinal mucosa", CANC CHEMOT, 43(6), 1999, pp. 520-521
16. Tranchand, B; Amsellem, C; Chatelut, E; Freyer, G; Iliadis, A; Ligneau, B; Trillet-Lenoir, V; Canal, P; Lochon, I; Ardiet, CJ
    A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    B. Tranchand et al., "A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients", CANC CHEMOT, 43(4), 1999, pp. 316-322
17. Chatelut, E; Rostaing, L; Gregoire, N; Payen, JL; Pujol, A; Izopet, J; Houin, G; Canal, P
    A pharmacokinetic model for alpha interferon administered subcutaneously
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    E. Chatelut et al., "A pharmacokinetic model for alpha interferon administered subcutaneously", BR J CL PH, 47(4), 1999, pp. 365-371
18. Gladieff, L; Chatelut, E; Gaspard, MH; Skaf, R; de Forni, M; Mihura, J; Canal, P; Bugat, R
    Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study
    BULLETIN DU CANCER
    
    L. Gladieff et al., "Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study", B CANCER, 86(7-8), 1999, pp. 673-677
19. Canal, P; Gautie, L; Gregoire, N; Perdaems, N; Chatelut, E
    News on the pharmacokinetics of anticancer drags
    BULLETIN DU CANCER
    
    P. Canal et al., "News on the pharmacokinetics of anticancer drags", B CANCER, 86(1), 1999, pp. 85-89
20. Guichard, S; Terret, C; Hennebelle, I; Lochon, I; Chevreau, P; Fretigny, E; Selves, J; Chatelut, E; Bugat, R; Canal, P
    CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues
    BRITISH JOURNAL OF CANCER
    
    S. Guichard et al., "CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues", BR J CANC, 80(3-4), 1999, pp. 364-370
21. Simeon, N; Chatelut, E; Canal, P; Nertz, M; Couderc, F
    Anthracycline analysis by capillary electrophoresis - Application to the analysis of daunorubicine in Kaposi sarcoma tumor
    JOURNAL OF CHROMATOGRAPHY A
    
    N. Simeon et al., "Anthracycline analysis by capillary electrophoresis - Application to the analysis of daunorubicine in Kaposi sarcoma tumor", J CHROMAT A, 853(1-2), 1999, pp. 449-454
22. ROSTAING L; CHATELUT E; PAYEN JL; IZOPET J; THALAMAS C; TONTHAT H; PASCAL JP; DURAND D; CANAL P
    PHARMACOKINETICS OF ALPHA-IFN-2B IN CHRONIC HEPATITIS-C VIRUS PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS OR WITH NORMAL RENAL-FUNCTION - CLINICAL IMPLICATIONS
    Journal of the American Society of Nephrology
    
    L. Rostaing et al., "PHARMACOKINETICS OF ALPHA-IFN-2B IN CHRONIC HEPATITIS-C VIRUS PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS OR WITH NORMAL RENAL-FUNCTION - CLINICAL IMPLICATIONS", Journal of the American Society of Nephrology, 9(12), 1998, pp. 2344-2348
23. ETIENNE MC; CHATELUT E; PIVOT X; LAVIT M; PUJOL A; CANAL P; MILANO G
    CO-VARIABLES INFLUENCING 5-FLUOROURACIL CLEARANCE DURING CONTINUOUS VENOUS INFUSION - A NONMEM ANALYSIS
    European journal of cancer
    
    M.C. Etienne et al., "CO-VARIABLES INFLUENCING 5-FLUOROURACIL CLEARANCE DURING CONTINUOUS VENOUS INFUSION - A NONMEM ANALYSIS", European journal of cancer, 34(1), 1998, pp. 92-97
24. BEKRADDA M; CHATELUT E; CVITKOVIC E; SOULIE P; CANAL P; MISSET JL; DUPONTANDRE G; BENSMAINE MA; BUGAT R
    PHARMACOKINETICS (PK) AND PHARMACODYNAMICS OF THE CARBOPLATIN (CBDCA)OXALIPLATIN (L-OHP) COMBINATION IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES - PRELIMINARY-RESULTS OF AN ONGOING PHASE-I TRIAL/
    Annals of oncology
    
    M. Bekradda et al., "PHARMACOKINETICS (PK) AND PHARMACODYNAMICS OF THE CARBOPLATIN (CBDCA)OXALIPLATIN (L-OHP) COMBINATION IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES - PRELIMINARY-RESULTS OF AN ONGOING PHASE-I TRIAL/", Annals of oncology, 9, 1998, pp. 447-447
25. DOZ F; URIEN S; CHATELUT E; MICHON J; RUBIE H; ZUCKER JM; CANAL P; BASTIAN G
    A LIMITED-SAMPLING METHOD FOR EVALUATION OF THE AREA-UNDER-THE-CURVE OF ULTRAFILTERABLE CARBOPLATIN IN CHILDREN
    Cancer chemotherapy and pharmacology
    
    F. Doz et al., "A LIMITED-SAMPLING METHOD FOR EVALUATION OF THE AREA-UNDER-THE-CURVE OF ULTRAFILTERABLE CARBOPLATIN IN CHILDREN", Cancer chemotherapy and pharmacology, 42(3), 1998, pp. 250-254
26. GUICHARD S; CHATELUT E; LOCHON I; BUGAT R; MAHJOUBI M; CANAL P
    COMPARISON OF THE PHARMACOKINETICS AND EFFICACY OF IRINOTECAN AFTER ADMINISTRATION BY THE INTRAVENOUS VERSUS INTRAPERITONEAL ROUTE IN MICE
    Cancer chemotherapy and pharmacology
    
    S. Guichard et al., "COMPARISON OF THE PHARMACOKINETICS AND EFFICACY OF IRINOTECAN AFTER ADMINISTRATION BY THE INTRAVENOUS VERSUS INTRAPERITONEAL ROUTE IN MICE", Cancer chemotherapy and pharmacology, 42(2), 1998, pp. 165-170
27. NGUYEN L; CHATELUT E; CHEVREAU C; TRANCHAND B; LOCHON I; BACHAUD JM; PUJOL A; HOUIN G; BUGAT R; CANAL P
    POPULATION PHARMACOKINETICS OF TOTAL AND UNBOUND ETOPOSIDE
    Cancer chemotherapy and pharmacology
    
    L. Nguyen et al., "POPULATION PHARMACOKINETICS OF TOTAL AND UNBOUND ETOPOSIDE", Cancer chemotherapy and pharmacology, 41(2), 1998, pp. 125-132
28. JOQUEVIEL C; MARTINO R; GILARD V; MALETMARTINO M; CANAL P; NIEMEYER U
    URINARY-EXCRETION OF CYCLOPHOSPHAMIDE IN HUMANS, DETERMINED BY P-31 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY
    Drug metabolism and disposition
    
    C. Joqueviel et al., "URINARY-EXCRETION OF CYCLOPHOSPHAMIDE IN HUMANS, DETERMINED BY P-31 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY", Drug metabolism and disposition, 26(5), 1998, pp. 418-428
29. MONSARRAT B; CHATELUT E; ROYER I; ALVINERIE P; DUBOIS J; DEZEUSE A; ROCHE H; CROS S; WRIGHT M; CANAL P
    MODIFICATION OF PACLITAXEL METABOLISM IN A CANCER-PATIENT BY INDUCTION OF CYTOCHROME-P450 3A4
    Drug metabolism and disposition
    
    B. Monsarrat et al., "MODIFICATION OF PACLITAXEL METABOLISM IN A CANCER-PATIENT BY INDUCTION OF CYTOCHROME-P450 3A4", Drug metabolism and disposition, 26(3), 1998, pp. 229-233
30. Perdaems, N; Bachaud, JM; Rouzaud, P; Murris-Espin, M; Hermant, C; Mihura, J; Lochon, I; Houin, G; Canal, P; Chatelut, E
    Relation between unbound plasma concentrations and toxicity in a prolongedoral etoposide schedule
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    N. Perdaems et al., "Relation between unbound plasma concentrations and toxicity in a prolongedoral etoposide schedule", EUR J CL PH, 54(9-10), 1998, pp. 677-683
31. GUIMBAUD R; GUICHARD S; BERTRAND V; APARICIO T; TERRET C; BUGAT R; COUTURIER D; CHATELUT E; CANAL P; CHAUSSADE S
    VARIABILITY OF DIHYDROPYRIMIDINE DESHYDROGENASE (DPD) ACTIVITY IN NORMAL, INFLAMMATORY AND TUMORAL TISSUES OF COLON AND LIVER IN HUMANS
    Gastroenterology
    
    R. Guimbaud et al., "VARIABILITY OF DIHYDROPYRIMIDINE DESHYDROGENASE (DPD) ACTIVITY IN NORMAL, INFLAMMATORY AND TUMORAL TISSUES OF COLON AND LIVER IN HUMANS", Gastroenterology, 114(4), 1998, pp. 2483-2483
32. Canal, P; Chatelut, E; Guichard, S
    Practical treatment guide for dose individualisation in cancer chemotherapy
    DRUGS
    
    P. Canal et al., "Practical treatment guide for dose individualisation in cancer chemotherapy", DRUGS, 56(6), 1998, pp. 1019-1038
33. MARTIN L; CHATELUT E; BONEU A; ROSTAING L; ROUSSILHES C; CASELLES O; CANAL P
    IMPROVEMENT OF THE COCKCROFT-GAULT EQUATION FOR PREDICTING GLOMERULAR-FILTRATION IN CANCER-PATIENTS
    Bulletin du cancer
    
    L. Martin et al., "IMPROVEMENT OF THE COCKCROFT-GAULT EQUATION FOR PREDICTING GLOMERULAR-FILTRATION IN CANCER-PATIENTS", Bulletin du cancer, 85(7), 1998, pp. 631-636
34. Gautie, L; Canal, P; Menguy, A; Latour, JF; Benard, I; Courbard, M; Brunelle, P; Carpentier, Y; Pinguet, F; Chevrier, R; Doly, M; Watelet, M; Briere, M; Viau, P; Duban, M; German, O; Gosselin, P; de La Jarrige, PL; Bertrand, C; Pommier, M; Prebay, D
    Analysis of medical prescription of granulocyte-colony stimulating factorsin 19 French anticancer centers
    BULLETIN DU CANCER
    
    L. Gautie et al., "Analysis of medical prescription of granulocyte-colony stimulating factorsin 19 French anticancer centers", B CANCER, 85(12), 1998, pp. 1043-1048
35. Chabot, GG; Robert, J; Lokiec, F; Canal, P
    Irinotecan pharmacokinetics
    BULLETIN DU CANCER
    
    G.G. Chabot et al., "Irinotecan pharmacokinetics", B CANCER, 1998, pp. 11-20
36. GUICHARD S; HENNEBELLE I; BUGAT R; CANAL P
    CELLULAR INTERACTIONS OF 5-FLUOROURACIL AND THE CAMPTOTHECIN ANALOG CPT-11 (IRINOTECAN) IN A HUMAN COLORECTAL-CARCINOMA CELL-LINE
    Biochemical pharmacology
    
    S. Guichard et al., "CELLULAR INTERACTIONS OF 5-FLUOROURACIL AND THE CAMPTOTHECIN ANALOG CPT-11 (IRINOTECAN) IN A HUMAN COLORECTAL-CARCINOMA CELL-LINE", Biochemical pharmacology, 55(5), 1998, pp. 667-676
37. RIVORY LP; HAAZ MC; CANAL P; LOKIEC F; ARMAND JP; ROBERT J
    PHARMACOKINETIC INTERRELATIONSHIPS OF IRINOTECAN (CPT-11) AND ITS 3 MAJOR PLASMA METABOLITES IN PATIENTS ENROLLED IN PHASE-I II TRIALS/
    Clinical cancer research
    
    L.P. Rivory et al., "PHARMACOKINETIC INTERRELATIONSHIPS OF IRINOTECAN (CPT-11) AND ITS 3 MAJOR PLASMA METABOLITES IN PATIENTS ENROLLED IN PHASE-I II TRIALS/", Clinical cancer research, 3(8), 1997, pp. 1261-1266
38. GUIMBAUD R; BUGAT R; VANCUTSEM E; MIGNARD D; MAHJOUBI M; CANAL P; BLANC C
    CONSISTENT SAFETY AND EFFICACY RESULTS IN 2 STUDY POPULATIONS TREATEDWITH IRINOTECAN (CPT-11) FOR METASTATIC COLORECTAL-CANCER (MCRC) RESISTANT TO 5-FU
    European journal of cancer
    
    R. Guimbaud et al., "CONSISTENT SAFETY AND EFFICACY RESULTS IN 2 STUDY POPULATIONS TREATEDWITH IRINOTECAN (CPT-11) FOR METASTATIC COLORECTAL-CANCER (MCRC) RESISTANT TO 5-FU", European journal of cancer, 33, 1997, pp. 736-736
39. BENEZET S; CHATELUT E; GUIMBAUD R; CHEVREAU C; BUGAT R; CANAL P
    IS CHATELUT FORMULA APPLICABLE IN OBESE PATIENTS FOR PREDICTING CARBOPLATIN CLEARANCE
    European journal of cancer
    
    S. Benezet et al., "IS CHATELUT FORMULA APPLICABLE IN OBESE PATIENTS FOR PREDICTING CARBOPLATIN CLEARANCE", European journal of cancer, 33, 1997, pp. 1123-1123
40. BENEZET S; GUIMBAUD R; CHATELUT E; CHEVREAU C; BUGAT R; CANAL P
    HOW TO PREDICT CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL CHARACTERISTICS IN OBESE PATIENTS
    Annals of oncology
    
    S. Benezet et al., "HOW TO PREDICT CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL CHARACTERISTICS IN OBESE PATIENTS", Annals of oncology, 8(6), 1997, pp. 607-609
41. BACHAUD JM; CHATELUT E; CANAL P; ALBIN N; YARDENI E; DAVID JM; SERRANO E; DALYSCHVEITZER N
    RADIOTHERAPY WITH CONCOMITANT CONTINUOUS CISPLATIN INFUSION FOR UNRESECTABLE TUMORS OF THE UPPER AERODIGESTIVE TRACT - RESULTS OF A PHASE-ISTUDY
    American journal of clinical oncology
    
    J.M. Bachaud et al., "RADIOTHERAPY WITH CONCOMITANT CONTINUOUS CISPLATIN INFUSION FOR UNRESECTABLE TUMORS OF THE UPPER AERODIGESTIVE TRACT - RESULTS OF A PHASE-ISTUDY", American journal of clinical oncology, 20(1), 1997, pp. 1-5
42. PINGUET F; MARTEL P; FABBRO M; PETIT I; CANAL P; CULINE S; ASTRE C; BRESSOLLE F
    PHARMACOKINETICS OF HIGH-DOSE INTRAVENOUS MELPHALAN IN PATIENTS UNDERGOING PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITOR-CELL TRANSPLANTATION
    Anticancer research
    
    F. Pinguet et al., "PHARMACOKINETICS OF HIGH-DOSE INTRAVENOUS MELPHALAN IN PATIENTS UNDERGOING PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITOR-CELL TRANSPLANTATION", Anticancer research, 17(1B), 1997, pp. 605-611
43. GUICHARD S; CUSSAC D; HENNEBELLE I; BUGAT R; CANAL P
    SEQUENCE-DEPENDENT ACTIVITY OF THE IRINOTECAN-5FU COMBINATION IN HUMAN COLON-CANCER MODEL HT-29 IN-VITRO AND IN-VIVO
    International journal of cancer
    
    S. Guichard et al., "SEQUENCE-DEPENDENT ACTIVITY OF THE IRINOTECAN-5FU COMBINATION IN HUMAN COLON-CANCER MODEL HT-29 IN-VITRO AND IN-VIVO", International journal of cancer, 73(5), 1997, pp. 729-734
44. BENEZET S; CHATELUT E; BAGHERI H; RIGALHUGUET F; NGUYEN L; POURRAT J; ROBERT A; MONTASTRUC JL; CANAL P
    INEFFICACY OF EXCHANGE-TRANSFUSION IN A METHOTREXATE INTOXICATION
    Bulletin du cancer
    
    S. Benezet et al., "INEFFICACY OF EXCHANGE-TRANSFUSION IN A METHOTREXATE INTOXICATION", Bulletin du cancer, 84(8), 1997, pp. 788-790
45. EVENE E; CHATELUT E; TRANCHAND B; CANAL P; LOCHON I; ILIADIS A; ARDIET CJ
    BAYESIAN-ESTIMATION OF ETOPOSIDE PHARMACO KINETIC PARAMETERS
    Bulletin du cancer
    
    E. Evene et al., "BAYESIAN-ESTIMATION OF ETOPOSIDE PHARMACO KINETIC PARAMETERS", Bulletin du cancer, 84(7), 1997, pp. 699-703
46. CALIARO MJ; VITAUX P; LAFON C; LOCHON I; NEHME A; VALETTE A; CANAL P; BUGAT R; JOZAN S
    MULTIFACTORIAL MECHANISM FOR THE POTENTIATION OF CISPLATIN (CDDP) CYTOTOXICITY BY ALL-TRANS-RETINOIC ACID (ATRA) IN HUMAN OVARIAN-CARCINOMACELL-LINES
    British Journal of Cancer
    
    M.J. Caliaro et al., "MULTIFACTORIAL MECHANISM FOR THE POTENTIATION OF CISPLATIN (CDDP) CYTOTOXICITY BY ALL-TRANS-RETINOIC ACID (ATRA) IN HUMAN OVARIAN-CARCINOMACELL-LINES", British Journal of Cancer, 75(3), 1997, pp. 333-340
47. CHATELUT E; CHEVREAU C; CANAL P
    PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS - RESPONSE
    Journal of the National Cancer Institute
    
    E. Chatelut et al., "PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS - RESPONSE", Journal of the National Cancer Institute, 89(3), 1997, pp. 261-262
48. CANAL P; GAY C; DEZEUZE A; DOUILLARD JY; BUGAT R; BRUNET R; ADENIS A; HERAIT P; LOKIEC F; MATHIEUBOUE A
    PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER
    Journal of clinical oncology
    
    P. Canal et al., "PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER", Journal of clinical oncology, 14(10), 1996, pp. 2688-2695
49. CHATELUT E; BODDY AV; PENG B; RUBIE H; LAVIT M; DEZEUZE A; PEARSON ADJ; ROCHE H; ROBERT A; NEWELL DR; CANAL P
    POPULATION PHARMACOKINETICS OF CARBOPLATIN IN CHILDREN
    Clinical pharmacology and therapeutics
    
    E. Chatelut et al., "POPULATION PHARMACOKINETICS OF CARBOPLATIN IN CHILDREN", Clinical pharmacology and therapeutics, 59(4), 1996, pp. 436-443
50. CANAL P; CHATELUT E
    DOSE OPTIMIZATION IN CLINICAL ONCOLOGY - PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS
    Bulletin du cancer
    
    P. Canal e E. Chatelut, "DOSE OPTIMIZATION IN CLINICAL ONCOLOGY - PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS", Bulletin du cancer, 83(4), 1996, pp. 256-265
51. LOKIEC F; CANAL P; MATHIEUBOUE A; ARMAND JP; BUGAT R
    CPT-11 METABOLISM IN BLOOD, BILE AND URINE IN CANCER-PATIENTS
    European journal of cancer
    
    F. Lokiec et al., "CPT-11 METABOLISM IN BLOOD, BILE AND URINE IN CANCER-PATIENTS", European journal of cancer, 31A, 1995, pp. 947-947
52. RIVORY LP; CANAL P; MATHIEUBOUE A; ROBERT J
    PHARMACOKINETICS AND INTERCONVERSION OF THE CARBOXYLATE AND LACTONE FORMS OF IRINOTECAN (CPT-11) AND OF ITS METABOLITE SN-38 IN PATIENTS
    European journal of cancer
    
    L.P. Rivory et al., "PHARMACOKINETICS AND INTERCONVERSION OF THE CARBOXYLATE AND LACTONE FORMS OF IRINOTECAN (CPT-11) AND OF ITS METABOLITE SN-38 IN PATIENTS", European journal of cancer, 31A, 1995, pp. 956-956
53. LOKIEC F; CANAL P; GAY C; CHATELUT E; ARMAND JP; ROCHE H; BUGAT R; GONCALVES E; MATHIEUBOUE A
    PHARMACOKINETICS OF IRINOTECAN AND ITS METABOLITES IN HUMAN BLOOD, BILE, AND URINE
    Cancer chemotherapy and pharmacology
    
    F. Lokiec et al., "PHARMACOKINETICS OF IRINOTECAN AND ITS METABOLITES IN HUMAN BLOOD, BILE, AND URINE", Cancer chemotherapy and pharmacology, 36(1), 1995, pp. 79-82
54. CHATELUT E; CHEVREAU C; BRUNNER V; MARTINEZ M; HOUIN G; BUGAT R; CANAL P
    A PHARMACOLOGICALLY GUIDED PHASE-I STUDY OF CARBOPLATIN COMBINATION WITH METHOTREXATE AND VINBLASTINE IN ADVANCED UROTHELIAL CANCER
    Cancer chemotherapy and pharmacology
    
    E. Chatelut et al., "A PHARMACOLOGICALLY GUIDED PHASE-I STUDY OF CARBOPLATIN COMBINATION WITH METHOTREXATE AND VINBLASTINE IN ADVANCED UROTHELIAL CANCER", Cancer chemotherapy and pharmacology, 35(5), 1995, pp. 391-396
55. BRUNNER V; HOUYAU P; CHATELUT E; ROCHE H; CANAL P
    CEREBROSPINAL-FLUID CONCENTRATIONS OF CARBOPLATIN IN A PATIENT WITHOUT BLOOD-BRAIN-BARRIER DISRUPTION
    Cancer chemotherapy and pharmacology
    
    V. Brunner et al., "CEREBROSPINAL-FLUID CONCENTRATIONS OF CARBOPLATIN IN A PATIENT WITHOUT BLOOD-BRAIN-BARRIER DISRUPTION", Cancer chemotherapy and pharmacology, 35(4), 1995, pp. 352-353
56. NEHME A; ALBIN N; CALIARO MJ; GUICHARD S; JOZAN S; JULIA AM; BUGAT R; CANAL P
    MECHANISM OF INTERACTION BETWEEN CISPLATIN AND HUMAN RECOMBINANT INTERFERON-GAMMA IN HUMAN OVARIAN-CANCER CELL-LINES
    International journal of cancer
    
    A. Nehme et al., "MECHANISM OF INTERACTION BETWEEN CISPLATIN AND HUMAN RECOMBINANT INTERFERON-GAMMA IN HUMAN OVARIAN-CANCER CELL-LINES", International journal of cancer, 61(5), 1995, pp. 643-648
57. LAVIT M; CHEVREAU C; CHATELUT E; DEFENIN V; LOCHON I; HOUIN G; BUGAT R; CANAL P
    RELATIONSHIPS BETWEEN HEMATOLOGICAL TOXIC ITY AND TOTAL AND FREE ETOPOSIDE PLASMATIC LEVELS WITH DAILY ORAL ETOPOSIDE ADMINISTRATION
    Bulletin du cancer
    
    M. Lavit et al., "RELATIONSHIPS BETWEEN HEMATOLOGICAL TOXIC ITY AND TOTAL AND FREE ETOPOSIDE PLASMATIC LEVELS WITH DAILY ORAL ETOPOSIDE ADMINISTRATION", Bulletin du cancer, 82(8), 1995, pp. 660-664
58. CHATELUT E; DEZEUZE A; LAVIT M; CHEVREAU C; PUJOL A; BONEU A; ROCHE H; HOUIN G; BUGAT R; CANAL P
    PREDICTION OF CARBOPLATINE CLEARANCE FROM MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS
    Bulletin du cancer
    
    E. Chatelut et al., "PREDICTION OF CARBOPLATINE CLEARANCE FROM MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS", Bulletin du cancer, 82(11), 1995, pp. 946-953
59. NOUADJE G; RUBIE H; CHATELUT E; CANAL P; NERTZ M; PUIG P; COUDERC F
    CHILD CEREBROSPINAL-FLUID ANALYSIS BY CAPILLARY ELECTROPHORESIS AND LASER-INDUCED FLUORESCENCE DETECTION
    Journal of chromatography
    
    G. Nouadje et al., "CHILD CEREBROSPINAL-FLUID ANALYSIS BY CAPILLARY ELECTROPHORESIS AND LASER-INDUCED FLUORESCENCE DETECTION", Journal of chromatography, 717(1-2), 1995, pp. 293-298
60. CHATELUT E; CANAL P; BRUNNER V; CHEVREAU C; PUJOL A; BONEU A; ROCHE H; HOUIN G; BUGAT R
    PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS
    Journal of the National Cancer Institute
    
    E. Chatelut et al., "PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS", Journal of the National Cancer Institute, 87(8), 1995, pp. 573-580
61. NEHME A; JULIA AM; JOZAN S; CHEVREAU C; BUGAT R; CANAL P
    MODULATION OF CISPLATIN CYTOTOXICITY BY HUMAN RECOMBINANT INTERFERON-GAMMA IN HUMAN OVARIAN-CANCER CELL-LINES
    European journal of cancer
    
    A. Nehme et al., "MODULATION OF CISPLATIN CYTOTOXICITY BY HUMAN RECOMBINANT INTERFERON-GAMMA IN HUMAN OVARIAN-CANCER CELL-LINES", European journal of cancer, 30A(4), 1994, pp. 520-525
62. ATTAL M; CANAL P; SCHLAIFER D; CHATELUT E; DEZEUZE A; HUGUET F; PAYEN C; PRIS J; LAURENT G
    ESCALATING DOSE OF MITOXANTRONE WITH HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE IN PATIENTS WITH REFRACTORY LYMPHOMA UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    Journal of clinical oncology
    
    M. Attal et al., "ESCALATING DOSE OF MITOXANTRONE WITH HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE IN PATIENTS WITH REFRACTORY LYMPHOMA UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION", Journal of clinical oncology, 12(1), 1994, pp. 141-148
63. SCHLAIFER D; ATTAL M; HUGUET F; CANAL P; LAURENT G; PRIS J
    ESCALATING DOSE OF MITOXANTRONE WITH HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE IN REFRACTORY LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    Seminars in hematology
    
    D. Schlaifer et al., "ESCALATING DOSE OF MITOXANTRONE WITH HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE IN REFRACTORY LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION", Seminars in hematology, 31(2), 1994, pp. 31-31
64. ATTAL M; CANAL P; SCHLAIFER D; PRIS J; LAURENT G
    SIGNIFICANCE OF HIGH-DOSAGE MITOXANTRONE IN MANAGEMENT OF MALIGNANT-LYMPHOMAS
    Nouvelle revue francaise d'hematologie
    
    M. Attal et al., "SIGNIFICANCE OF HIGH-DOSAGE MITOXANTRONE IN MANAGEMENT OF MALIGNANT-LYMPHOMAS", Nouvelle revue francaise d'hematologie, 36, 1994, pp. 190000149-190000149
65. CHATELUT E; ROSTAING L; GUALANO V; VISSAC T; DEFORNI M; TONTHAT H; SUC JM; HOUIN G; CANAL P
    PHARMACOKINETICS OF CARBOPLATIN IN A PATIENT SUFFERING FROM ADVANCED OVARIAN-CARCINOMA WITH HEMODIALYSIS-DEPENDENT PENAL INSUFFICIENCY
    Nephron
    
    E. Chatelut et al., "PHARMACOKINETICS OF CARBOPLATIN IN A PATIENT SUFFERING FROM ADVANCED OVARIAN-CARCINOMA WITH HEMODIALYSIS-DEPENDENT PENAL INSUFFICIENCY", Nephron, 66(2), 1994, pp. 157-161
66. RIVORY LP; CHATELUT E; CANAL P; MATHIEUBOUE A; ROBERT J
    KINETICS OF THE IN-VIVO INTERCONVERSION OF THE CARBOXYLATE AND LACTONE FORMS OF IRINOTECAN (CPT-11) AND OF ITS METABOLITE SN-38 IN PATIENTS
    Cancer research
    
    L.P. Rivory et al., "KINETICS OF THE IN-VIVO INTERCONVERSION OF THE CARBOXYLATE AND LACTONE FORMS OF IRINOTECAN (CPT-11) AND OF ITS METABOLITE SN-38 IN PATIENTS", Cancer research, 54(24), 1994, pp. 6330-6333
67. BACHAUD JM; ALBIN N; GAY C; CHATELUT E; BENCHALAL M; DAVID JM; BONEU A; SERRANO E; CANAL P; DALYSCHVEITZER N
    CONCOMITANT RADIOCHEMOTHERAPY (CDDP 4-6 M G M2/D) IN LOCALLY ADVANCEDHEAD AND NECK-CANCER/
    Bulletin du cancer
    
    J.M. Bachaud et al., "CONCOMITANT RADIOCHEMOTHERAPY (CDDP 4-6 M G M2/D) IN LOCALLY ADVANCEDHEAD AND NECK-CANCER/", Bulletin du cancer, 81(3), 1994, pp. 212-218
68. NEHME A; ALBIN N; JULIA AM; JOZAN S; BUGAT R; CANAL P
    MECHANISMS OF INTERACTION BETWEEN CISPLAT IN AND HUMAN RECOMBINANT INTERFERON-GAMMA (INF-GAMMA) IN HUMAN OVARIAN-CANCER CELL-LINES
    Bulletin du cancer
    
    A. Nehme et al., "MECHANISMS OF INTERACTION BETWEEN CISPLAT IN AND HUMAN RECOMBINANT INTERFERON-GAMMA (INF-GAMMA) IN HUMAN OVARIAN-CANCER CELL-LINES", Bulletin du cancer, 81(11), 1994, pp. 934-934
69. JULIA AM; ROCHE H; BERLION M; LUCAS C; MILANO G; ROBERT J; BIZZARI JP; CANAL P
    MULTIDRUG-RESISTANCE CIRCUMVENTION HY A NEW TRIAZINOAMINOPIPERIDINE DERIVATIVE S9788 IN-VITRO - DEFINITION OF THE OPTIMAL SCHEDULE AND COMPARISON WITH VERAPAMIL
    British Journal of Cancer
    
    A.M. Julia et al., "MULTIDRUG-RESISTANCE CIRCUMVENTION HY A NEW TRIAZINOAMINOPIPERIDINE DERIVATIVE S9788 IN-VITRO - DEFINITION OF THE OPTIMAL SCHEDULE AND COMPARISON WITH VERAPAMIL", British Journal of Cancer, 69(5), 1994, pp. 868-874
70. MULLER C; CHATELUT E; GUALANO V; DEFORNI M; HUGUET F; ATTAL M; CANAL P; LAURENT G
    CELLULAR PHARMACOKINETICS OF DOXORUBICIN IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA - COMPARISON OF BOLUS ADMINISTRATION AND CONTINUOUS-INFUSION
    Cancer chemotherapy and pharmacology
    
    C. Muller et al., "CELLULAR PHARMACOKINETICS OF DOXORUBICIN IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA - COMPARISON OF BOLUS ADMINISTRATION AND CONTINUOUS-INFUSION", Cancer chemotherapy and pharmacology, 32(5), 1993, pp. 379-384
71. ROCHE H; JULIA AM; JOZAN S; MULLER C; DASTUGUE N; ARQUIER MA; MARQUES B; LAURENT G; CANAL P
    CHARACTERIZATION AND CHEMOSENSITIVITY OF A HUMAN EPITHELIOID SARCOMA CELL-LINE (SARCCR-2)
    International journal of cancer
    
    H. Roche et al., "CHARACTERIZATION AND CHEMOSENSITIVITY OF A HUMAN EPITHELIOID SARCOMA CELL-LINE (SARCCR-2)", International journal of cancer, 54(4), 1993, pp. 663-668
72. CANAL P; ATTAL M; CHATELUT E; GUICHARD S; HUGUET F; MULLER C; SCHLAIFER D; LAURENT G; HOUIN G; BUGAT R
    PLASMA AND CELLULAR PHARMACOKINETICS OF MITOXANTRONE IN HIGH-DOSE CHEMOTHERAPEUTIC REGIMEN FOR REFRACTORY LYMPHOMAS
    Cancer research
    
    P. Canal et al., "PLASMA AND CELLULAR PHARMACOKINETICS OF MITOXANTRONE IN HIGH-DOSE CHEMOTHERAPEUTIC REGIMEN FOR REFRACTORY LYMPHOMAS", Cancer research, 53(20), 1993, pp. 4850-4854
73. DEFORNI M; GUALANO V; CANAL P; MARTEL P; IZARSOUM F; CHEVREAU C; SOULIE P; ROCHE H; BUGAT R
    CONTINUOUS-INFUSION OF 5-FLUOROURACIL BY DOUBLE ROUTE (INTRAVENOUS AND INTRAPERITONEAL) WITH MODULATION BY FOLINIC ACID - CLINICAL AND PHARMACOKINETIC, PHASE-I STUDY IN PATIENTS WITH INTRAABDOMINAL MALIGNANCIES
    Bulletin du cancer
    
    M. Deforni et al., "CONTINUOUS-INFUSION OF 5-FLUOROURACIL BY DOUBLE ROUTE (INTRAVENOUS AND INTRAPERITONEAL) WITH MODULATION BY FOLINIC ACID - CLINICAL AND PHARMACOKINETIC, PHASE-I STUDY IN PATIENTS WITH INTRAABDOMINAL MALIGNANCIES", Bulletin du cancer, 80(5), 1993, pp. 408-417
74. SAMADIBABOLI M; FAVRE G; CANAL P; SOULA G
    LOW-DENSITY-LIPOPROTEIN FOR CYTOTOXIC DRUG TARGETING - IMPROVED ACTIVITY OF ELLIPTINIUM DERIVATIVE AGAINST B16 MELANOMA IN MICE
    British Journal of Cancer
    
    M. Samadibaboli et al., "LOW-DENSITY-LIPOPROTEIN FOR CYTOTOXIC DRUG TARGETING - IMPROVED ACTIVITY OF ELLIPTINIUM DERIVATIVE AGAINST B16 MELANOMA IN MICE", British Journal of Cancer, 68(2), 1993, pp. 319-326
75. HOUYAU P; GAY C; CHATELUT E; CANAL P; ROCHE H; MILANO G
    SEVERE FLUOROURACIL TOXICITY IN A PATIENT WITH DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY
    Journal of the National Cancer Institute
    
    P. Houyau et al., "SEVERE FLUOROURACIL TOXICITY IN A PATIENT WITH DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY", Journal of the National Cancer Institute, 85(19), 1993, pp. 1602-1603